The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ACE-Breast-02: A pivotal phase II/III trial of ARX788, a novel anti-HER2 antibody-drug conjugate (ADC), versus lapatinib plus capecitabine for HER2+ advanced breast cancer (ABC).
 
Xichun Hu
No Relationships to Disclose
 
Leiping Wang
No Relationships to Disclose
 
Jian Zhang
No Relationships to Disclose
 
Qingyuan Zhang
No Relationships to Disclose
 
Quchang Ouyang
No Relationships to Disclose
 
Xiaojia Wang
No Relationships to Disclose
 
Wei Li
No Relationships to Disclose
 
Weimin Xie
No Relationships to Disclose
 
Zhongsheng Tong
No Relationships to Disclose
 
Faliang Xu
No Relationships to Disclose
 
Wei Liu
No Relationships to Disclose
 
Shushen Wang
No Relationships to Disclose
 
Tao Sun
No Relationships to Disclose